Docoh
Loading...

NEO Neogenomics

News

From Benzinga Pro
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Raymond James Upgrades NeoGenomics to Outperform
14 Oct 21
News, Upgrades, Analyst Ratings
Raymond James analyst Andrew Cooper upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform.
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
4 Oct 21
M&A, News, Health Care, General
Bloomberg Reported Sunday Guardant Health Decided Against Buying NeoGenomics
4 Oct 21
M&A, News, Rumors
https://www.bloomberg.com/news/articles/2021-10-04/guardant-health-is-said-to-decide-against-neogenomics-takeover
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
1 Oct 21
M&A, News, Health Care, Movers, Trading Ideas, General
Neogenomics Shares Move Higher Amid Report Guardant Considering Takeover Of Co.
1 Oct 21
M&A, News, Rumors, Movers, Trading Ideas
-Bloomberg https://twitter.com/cfromhertz/status/1443924780328144896
NeoGenomics' Liquid Biopsy Subsidiary Inivata And Collaborators To Present Data That Further Validate The Application Of Its RaDaR(TM) MRD And InVisionFirst(R)-Lung Assays At The ESMO Congress 2021
9 Sep 21
News
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited
Earnings Scheduled For August 12, 2021
12 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Morgan Stanley Maintains Overweight on NeoGenomics, Lowers Price Target to $58
9 Aug 21
News, Price Target, Analyst Ratings
Morgan Stanley maintains NeoGenomics (NASDAQ:NEO) with a Overweight and lowers the price target from $64 to $58.
NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
6 Aug 21
Earnings, News, Guidance, Health Care, General
Recap: NeoGenomics Q2 Earnings
6 Aug 21
Earnings, News, Guidance
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).
NeoGenomics Q2 Adj. EPS $(0.01) Beats $(0.06) Estimate, Sales $122.00M Beat $118.16M Estimate
6 Aug 21
Earnings, News
NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 75 percent increase over losses of $(0.04) per share from the same
Earnings Scheduled For August 6, 2021
6 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.
NeoGenomics's Earnings: A Preview
5 Aug 21
Earnings
On Friday, August 06, NeoGenomics (NASDAQ:NEO) will release its latest earnings report. Here is Benzinga's outlook for the company.

Press releases

From Benzinga Pro
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
19 Oct 21
Press Releases
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays Two clinical studies including interventional RaDaR™ study Research Triangle Park, NC, USA
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
19 Oct 21
News, Press Releases
Two clinical studies including interventional RaDaR™ studyFT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
13 Oct 21
News, Press Releases
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its
NeoGenomics Announces Board of Directors' Transition
12 Oct 21
Management, Press Releases
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the yearFT. MYERS, FL / ACCESSWIRE /
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
9 Sep 21
News, Press Releases
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
1 Sep 21
Events, Press Releases
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
6 Aug 21
News, Press Releases
Second-Quarter 2021 Results and Highlights:Consolidated revenue increased 40% to $122 millionClinical Services revenue increased 37% to $101 millionPharma Services revenue increased 55% to $20 millionCompleted the